Showing results (1-10 of 30) with videos related to
Sort By:
Pageof 3
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|May 6, 2005
Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of lifeNowell Solish, Antranik Benohanian, Jonathan W Kowalski, et al.Plastic and Reconstructive Surgery|September 28, 2007
Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open-label studyMitchell A Stotland, Jonathan W Kowalski, Belinda B RayCurrent Medical Research and Opinion|July 20, 2013
An adherence based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%William B Wong, Vaishali D Patel, Jonathan W Kowalski, et al.Journal of the American Academy of Dermatology|July 29, 2004
US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national surveyDavid R Strutton, Jonathan W Kowalski, Dee Anna Glaser, et al.Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|May 20, 2003
Development of the Facial Lines Treatment Satisfaction Questionnaire and initial results for botulinum toxin type A-treated patientsSue Ellen Cox, J Charlie Finn, Lori Stetler, et al.Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|January 24, 2007
Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled studySteven Fagien, Sue Ellen Cox, J Charles Finn, et al.Dermatology (Basel, Switzerland)|May 19, 2006
Primary focal hyperhidrosis: disease characteristics and functional impairmentHenning Hamm, Markus K Naumann, Jonathan W Kowalski, et al.Clinical Ophthalmology (Auckland, N.Z.)|May 29, 2014
Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutionsJoanna H Campbell, Gail F Schwartz, Britni LaBounty, et al.Clinical Therapeutics|June 11, 2013
Psychometric performance of the incontinence quality-of-life questionnaire among patients with overactive bladder and urinary incontinenceDonald L Patrick, Kristin M Khalaf, Roger Dmochowski, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|May 7, 2013
Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitisRupali K Naik, Katharine S Gries, Anne M Rentz, et al.Pageof 3